FREE SHIPPING
On all US orders over $100
Get 15% off your first order:
100% Authentic K-Beauty
• Direct US Shipping
$28.00
Experience a new era of skin regeneration with the Medicube PDRN Pink Peptide Eye Cream, a high-performance clinical treatment designed to repair and densify the delicate orbital area. This advanced Eye Cream utilizes Salmon DNA (PDRN) and a specialized Pink Peptide complex to stimulate cellular recovery, making it an essential tool for those looking to reverse visible signs of environmental damage and chronological aging.
In stock
PDRN is a DNA-derived ingredient renowned in professional dermatology for its ability to accelerate tissue repair and improve skin elasticity. In this formula, Medicube pairs PDRN with “Pink Peptides” to target the structural integrity of the skin. By reinforcing the dermal-epidermal junction, this cream helps to “fill” hollow areas and smooth out fine lines from within.
When integrated into a routine for korean skin care under eye circles, the Medicube PDRN Pink Peptide Eye Cream works by improving skin density. Thicker, healthier skin is less translucent, which naturally masks the dark vascularity and shadows that often appear in the under-eye region.
| Feature | Medicube PDRN Pink Peptide | Standard Peptide Eye Cream |
| Key Active | PDRN (Salmon DNA) | Basic Signal Peptides |
| Primary Function | Tissue Regeneration & Repair | Surface Smoothing |
| Color/Texture | Natural Pink / Rich & Silky | White / Creamy |
| Target Concern | Deep Wrinkles & Skin Thinning | Fine Lines & Dryness |
| Clinical Focus | Medical-Grade Recovery | Cosmetic Maintenance |
The Medicube PDRN Pink Peptide Eye Cream is ideal for:
✔ Individuals concerned with thinning skin and loss of volume under the eyes.
✔ Those seeking a more advanced korean skin care under eye circles solution than basic hydration.
✔ Users looking to repair “splotchy” or uneven skin texture in the orbital area.
✔ Anyone interested in “Bio-Remodeling” products that use DNA-based technology.
Reviews
There are no reviews yet.